The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...
The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...
The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...
CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...
The firm's share price fell after a presentation at the conference revealed lower-than-expected Elevidys sales.
NEW YORK – Researchers at the University of Colorado Anschutz' Gates Institute just got a $1 million boost from Blood Cancer United to develop an anti-CD64 CAR T-cell therapy for acute myeloid ...
Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...
The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback